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SUMMARY
Acinetobacter is a well-recognized nosocomial pathogen. Previous reports of community-
associated Acinetobacter infections have lacked clear case definitions and assessment of 
healthcare-associated (HCA) risk factors. We identified Acinetobacter bacteraemia cases from 
blood cultures obtained <3 days after hospitalization in rural Thailand and performed medical 
record reviews to assess HCA risk factors in the previous year and compare clinical and 
microbiological characteristics between cases with and without HCA risk factors. Of 72 
Acinetobacter cases, 32 (44%) had no HCA risk factors. Compared to HCA infections, non-HCA 
infections were more often caused by Acinetobacter species other than calcoaceticus–baumannii 
complex species and by antibiotic-susceptible organisms. Despite similar symptoms, the case-
fatality proportion was lower in non-HCA than HCA cases (9% vs. 45%, P < 0·01). Clinicians 
should be aware of Acinetobacter as a potential cause of community-associated infections in 
Thailand; prospective studies are needed to improve understanding of associated risk factors and 
disease burden.
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The genus Acinetobacter currently comprises 30 named species [1] and multiple DNA–
DNA hybridization groups (genomic species) with provisional designations [2]. Several 
species, including members of the Acinetobacter calcoaceticus–A. baumannii (Acb) 
complex, which includes A. calcoaceticus and A. baumannii, among others, are well 
documented causes of nosocomial infections including pneumonia, meningitis and 
bacteraemia often with significant mortality [3]. Risk factors for nosocomial Acinetobacter 
infections include mechanical ventilation, central vascular catheterization, and prior 
antibiotic use [3, 4]. Acinetobacter species have acquired multiple drug-resistance 
mechanisms, making them increasingly difficult to treat and of particular public health 
concern [3]. In Thailand, marked increases in A. baumannii resistance to imipenem (from 
1·0 to 48·4% of isolates taken from patients in non-ICU wards) and other drugs were 
observed from 2000 to 2005 [5].
Several reports of ‘community-acquired’ Acinetobacter infections have described cases with 
onset outside the healthcare setting with mortality estimates ranging from 40–64% [6–13]. 
However, descriptions have been limited by the absence of a standard case definition and 
lack of assessment of healthcare-associated (HCA) risk factors. Acinetobacter species can 
colonize indwelling medical devices [14], skin [15], and mucosal surfaces [13, 16], making 
it possible that patients could acquire Acinetobacter in the health-care setting and then 
develop active infection after returning to the community, although this would remain as 
conjecture in the absence of strain-typing studies. Most reports of ‘community-acquired’ 
infection have not allowed for distinction between these HCA infections with onset in the 
community and community cases in patients without significant healthcare exposures. 
Descriptions have also been limited primarily to case reports or case series, mostly in adults, 
with very little data on infections in children.
The International Emerging Infections Program (IEIP), in collaboration with the Thailand 
Ministry of Public Health (MOPH), conducts active surveillance for bloodstream infections 
in two rural provinces in Thailand, Nakhon Phanom and Sa Kaeo. Early observations of 
unexpectedly high numbers of Acinetobacter bacteraemia cases in persons without known 
hospital exposures prompted further investigation. Using a rigorous case definition to 
minimize misclassification of HCA infections as community-associated, we describe clinical 
and microbiological characteristics of Acinetobacter bacteraemia cases in patients without 
apparent HCA exposures and compare these to cases with known HCA exposures.
METHODS
Setting
Sa Kaeo province is in eastern Thailand on the Cambodian border and has a population of 
550 000. Nakhon Phanom borders Laos in northeastern Thailand and has 751 000 residents. 
Both provinces have primarily agricultural-based economies. The 2010 per capita GDP was 
US$2303 in Sa Kaeo province and US$1290 in Nakhon Phanom province, ranking 51st and 
72nd of the 76 provinces in Thailand [17]. Thai citizens are entitled to universal healthcare 
which provides health services at a nominal or no charge.
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Surveillance for pneumonia and bloodstream infections
Active surveillance for hospitalized cases of community-acquired pneumonia has been 
conducted in all district (n=16) and military (n=2) hospitals (10–140 inpatient beds) as well 
as both provincial hospitals (225–327 beds) in Sa Kaeo and Nakhon Phanom provinces since 
2002–2003 [18, 19]. In 2005, automated blood culture systems (BacT/ALERT 3D®, 
bioMérieux, USA) were implemented in Sa Kaeo (May) and Nakhon Phanom (November). 
Blood cultures were performed at the clinicians’ discretion.
Two blood culture bottles were inoculated for each patient, a standard bottle to support 
aerobic growth [BacT/ALERT FA® (FA) for ages ≥5 years and BacT/ALERT PF® (PF) for 
ages <5 years] and a bottle to enhance growth of mycobacteria and other fastidious 
organisms [BacT/ALERT MB® (MB)]. If blood volume was insufficient to inoculate both 
bottles, only the FA/PF bottle was used and if collected at a district or military hospital, 
blood cultures were transported at 15–30 °C to the provincial hospital for processing within 
24 h. Bottles that indicated positive were subcultured by standard methods [20].
Laboratory methods
Suspected Acinetobacter isolates were identified in the hospital laboratories by phenotypic 
testing and confirmed at the Thailand National Institute of Health (NIH) using conventional 
biochemical testing [21–23]; any equivocal results by biochemical testing were confirmed 
by polymerase chain reaction at the NIH [24–26]. Isolates were grouped into two categories: 
(a) Acb complex which included A. baumannii, A. calcoaceticus, A. pittii (genospecies 3), A. 
nosocomialis (genospecies TU13), Acinetobacter genospecies close to TU13 and 
Acinetobacter genospecies between 1 and 3, and (b) non-Acb complex which included all 
other species. Antibiotic susceptibility testing was done using the disk diffusion method 
according to the Clinical and Laboratory Standards Institute’s guidelines [27, 28]. Isolates 
resistant to cefotaxime, amikacin, and imipenem were classified as multi-drug resistant 
(MDR) [13].
Data collection
We abstracted data on demographics, clinical characteristics, comorbidities, recent 
hospitalizations, and alcohol use and smoking from medical records of patients with 
Acinetobacter bacteraemia using a structured form. Trained research nurses and a study 
physician (S.T.) independently reviewed the charts and about half of the charts were audited 
by the study physician. When available, chest radiographs were reviewed and interpreted by 
a panel of radiologists to determine whether they were consistent with pneumonia [29].
Case definitions for Acinetobacter
We identified patients with Acinetobacter isolated from blood cultures between May 2005 
and December 2008. To minimize the possibility of including Acinetobacter-positive 
cultures that represented contamination, patients whose cultures became positive after 24 h 
of incubation or grew additional organisms were excluded. We then limited our analyses to 
patients with objective signs of active infection (temperature ≥38·0 °C or abnormal white 
blood cell count).
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We considered patients with Acinetobacter bacteraemia who had their blood cultured ≥3 
days after admission to have hospital-onset infections and patients whose blood was cultured 
<3 days after admission were considered to have community-onset infections [30]. Within 
the group with community-onset infections, patients were further differentiated between 
those with and without known HCA risk factors. Owing to the lack of standard definitions 
for community-associated Acinetobacter infections, criteria used to define community-
associated methicillin-resistant Staphylococcus aureus (MRSA) [31] were adapted to 
develop a list of HCA risk factors. These included hospitalization within the past year, 
residence in a nursing home, or any of the following within the previous 6 months: dialysis, 
renal disease, a surgical procedure, an indwelling urinary catheter, intermittent urinary 
catheterization, or a vascular access cannula.
Statistical methods
Two groups were compared: (1) patients with community-onset infections and no known 
HCA risk factors (henceforth referred to as non-HCA infections), and (2) patients with 
either hospital-onset infections or community-onset infections with known HCA risk factors 
(HCA infections). Using SAS v. 9.2 software (SAS Institute Inc., USA), we compared 
demographic, clinical, and microbiological characteristics between HCA and non-HCA 
cases; Pearson’s Χ2 test was used to assess statistical significance and an exact test was used 
when expected cell sizes were <5.
Ethical considerations
Medical record reviews were conducted under a protocol approved by a CDC Institutional 
Review Board (protocol no. 5694) and the Ethical Review Committee of the Thailand 
MOPH.
RESULTS
We identified 185 patients with Acinetobacter-positive blood cultures in Nakhon Phanom 
and Sa Kaeo provinces from May 2005 to December 2008. We excluded 65 patients because 
the Acinetobacter isolate was a possible contaminant (22 became positive after 24 h 
incubation and 43 cultures grew an additional organism), 28 patients without charts 
available for review, and 20 others with no objective evidence of active infection (Fig. 1). 
Of the remaining 72 patients with Acinetobacter bacteraemia, 52 had blood inoculated into 
both FA/FP and MB bottles; 22 (42%) of those were positive in both bottles. Acinetobacter 
was the seventh most common pathogen identified in patients with community-onset 
bacteraemia (i.e. blood cultured <3 days after admission, n=50) and the second most 
common in those with hospital-onset infection (n=22) (data not shown).
Thirty-two (44%) of the 72 patients had non-HCA infections and 40 (56%) had HCA 
infections. Of the 40 patients with HCA infections, 22 (55%) had their blood cultured ≥3 
days after admission; the remaining were considered HCA because the patient had at least 
one HCA risk factor. The most common HCA risk factor was a hospital admission within 
the past year. Two newborns that developed infection within 10 days after birth were 
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considered HCA cases but were excluded from further analysis because the implications of 
hospital exposure during birth were unclear.
Non-HCA cases tended to be younger than HCA cases (Table 1). Twenty-five Acinetobacter 
cases occurred in children aged ≤15 years (15 had non-HCA infections and 10 had HCA 
infections). Thirteen (87%) of 15 children aged ≤15 years with non-HCA infections and 
8/10 (80%) with HCA infections were from Nakhon Phanom. Six (40%) of the 15 children 
with non-HCA infections were diagnosed with pneumonia. One child with a non-HCA 
infection had been hospitalized with a second-degree scald burn and the following day 
developed high fever and had a seizure during surgical debridement. It is unclear whether 
this surgery led to introduction of a community pathogen that had contaminated his skin. 
Demographic and clinical characteristics of the children with non-HCA infections are 
detailed in Table 2.
Although patients with non-HCA infections were slightly more likely than patients with 
HCA infections to have a temperature ≥38 °C or a fever history, generally the two groups 
had similar signs and symptoms of disease. HCA patients were more likely to have 
underlying illnesses such as diabetes, chronic obstructive pulmonary disease, or heart 
disease (Table 3). The case-fatality proportion was lower in the non-HCA group [9% (3/32) 
vs. 45% (17/38), P < 0·01]. The three patients with non-HCA infections who died were a 38-
year-old with no recorded history of an underlying condition, admitted for alcohol 
withdrawal with delirium; a 59-year-old with a history of heart disease, hypertension, and 
dyspepsia, admitted with septicaemia and malnutrition; and a 61-year-old with no recorded 
history of an underlying condition, admitted for gastroenteritis of presumed infectious 
origin. Of these three patients, two (67%) had non-Acb complex isolates. Seventy-one per 
cent (12/17) of the deaths in patients with HCA infections occurred in patients who were 
aged ≥65 years. Of the 17 deaths in patients with HCA infections, one (6%) was a patient 
with a non-Acb complex isolate. The majority of admission diagnoses for patients with both 
non-HCA and HCA infections were infectious conditions, most commonly pneumonia 
(Table 3).
The proportion of Acinetobacter bacteraemia cases that were non-HCA was higher in 
Nakhon Phanom (66%, 27/41) than in Sa Kaeo (17%, 5/29). We did not observe marked 
seasonality or case clustering indicative of an outbreak in either province (Fig. 2).
Microbiological characteristics
Compared to HCA infections, a greater proportion of non-HCA infections were due to non-
Acb complex species (44% vs. 21%, P=0·04) (Table 1).
Antimicrobial resistance was common, especially in Acb complex isolates and isolates from 
HCA infections (Table 4). Imipenem resistance was common in Acb complex isolates: 
53·9% for HCA infections vs. 23·5% for non-HCA infections (P=0·05). Acb complex 
isolates from non-HCA infections were also less likely to be resistant to amoxicillin/
clavulanic acid and co-trimoxazole than those from HCA infections. These differences were 
not observed in isolates of non-Acb species. Twelve (30%) of the 40 Acb isolates tested for 
drug resistance were MDR compared to one (5%) of the 22 non-Acb isolates tested.
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We identified 72 Acinetobacter bacteraemia cases identified through bloodstream infection 
surveillance in two rural Thailand provinces from May 2005 to December 2008. Using a 
restrictive case definition to minimize misclassification, 32 cases occurred in patients with 
no identifiable HCA risk factors. The relatively high frequency of these infections, the high 
case-fatality proportion, and the high levels of resist ance to antibiotics frequently used for 
empirical treatment of sepsis and pneumonia underscore the need for clinician awareness of 
Acinetobacter as a potential cause of community-associated bacteraemia in Thailand.
Differences in microbiological characteristics of infecting isolates suggest that non-HCA 
Acinetobacter infections were epidemiologically distinct from HCA cases. Compared to 
HCA infections, non-HCA infections were more likely to be caused by non-Acb complex 
species and by isolates that were less commonly resistant to antibiotics. These differences 
support the a priori hypothesis that Acinetobacter acquisition occurred in different settings 
for patients with non-HCA vs. HCA infections (i.e. community vs. hospital acquisition). 
Although signs and symptoms of infection were similar, patients with HCA infections had a 
significantly higher case-fatality proportion and were, as expected, older and more likely to 
have comorbidities.
Non-HCA infections were more common in Nakhon Phanom and almost all of the non-HCA 
infections in children aged ≤15 years were from Nakhon Phanom. This may be a 
surveillance artifact, because blood cultures were more commonly performed in Nakhon 
Phanom, especially on children [18]. However, Acinetobacter infections may truly be more 
common in the Northeast compared to other regions of Thailand. It is well documented that 
Burkholderia pseudomallei, the cause of meliodosis and another soil organism, occurs at 
much higher rates in northeastern Thailand [32, 33]. Although the clinical relevance of 
environmental Acinetobacter exposures remains uncertain, the geographical distribution of 
Acinetobacter infections should be explored further to identify bacterial reservoirs and 
potential risk factors for infection. Carriage or environmental surveys may also help 
characterize community-associated risk.
We identified 15 children aged ≤15 years with community-onset Acinetobacter infections 
and no known HCA risk factors. These children had high fevers, elevated white blood cell 
counts, and clinical presentations consistent with systemic Acinetobacter infection, 
suggesting true infections and not contaminants. Children are virtually absent from the 
literature on community-onset Acinetobacter infections. One study identified a subset of 
children with infection onset in the community, but 96% of these had indwelling central 
venous catheters [9], a clear HCA risk factor, which was not present in the children 
described here.
Despite the fact that several of the 15 children with non-HCA infections were treated with 
antibiotics to which the infecting Acinetobacter species was not susceptible, all children 
recovered. This suggests that in vitro antibiotic resistance does not necessarily predict 
clinical failure or that some non-HCA Acinetobacter infections may resolve with sub-
optimal antibiotic therapy. However, given the limitations of this analysis, these data should 
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not be taken to support alternative treatment approaches to Acinetobacter infections. Instead, 
our results support the view that Acinetobacter should be considered in the evaluation of 
children with sepsis in rural Thailand and that antibiotic therapy should be guided by 
prevailing antibiotic resistance patterns.
Our results differed from previous reports of ‘community-acquired’ Acinetobacter 
infections. Our observed case-fatality proportion was lower (9%) in patients with non-HCA 
infections than the 58% 30-day mortality reported for patients with ‘community-acquired’ 
Acinetobacter pneumonia in Hong Kong [12] and an overall mortality of 44% in a review of 
‘community-acquired’ cases [11]. Indeed, the case-fatality proportion in previously reported 
‘community-acquired’ cases is more consistent with the case-fatality proportion observed 
for HCA infections (45%) in our analysis. Previous reports may have misclassified 
Acinetobacter cases because they defined community-acquired infection as any infection 
with community onset. However, we have demonstrated the importance of assessing HCA 
risk factors as 18/50 patients (36%) with community-onset infections had clear healthcare 
exposures that may have put them at risk for acquisition of Acinetobacter in a healthcare 
setting. An additional dissimilar result was that, although alcohol abuse was common in 
those with community-acquired disease in previous reports [11], alcohol use was only noted 
in 24% of adults in our series. In our study population, a relatively high proportion (72%) of 
non-HCA cases occurred in individuals without documented comorbid conditions or 
previously described risk factors, suggesting that additional work to identify risk factors is 
warranted.
Antimicrobial resistance was common, especially in Acb complex isolates, for which the 
proportion of resistant isolates exceeded that for non-Acb species for all antibiotics except 
co-trimoxazole. Particularly marked was the high proportion of resistance to imipenem 
(42%) in all Acb complex isolates and 54% of Acb complex isolates from HCA cases. The 
high proportion of resistant isolates is consistent with data from the National Antimicrobial 
Resistance Surveillance of Thailand (NARST), which has identified marked increases in 
imipenem resistance (62% of Acb complex isolates in 2010) [5]. These data highlight both 
the importance of local antimicrobial resistance data to guide treatment and the need for 
alternative treatment options. National and regional antimicrobial resistance surveillance 
should continue and efforts to reduce antimicrobial resistance (e.g. judicious antibiotic use 
education) should be strengthened.
Although not the focus of this analysis, our results demonstrate the importance of 
Acinetobacter as a cause of HCA infections, which were highly resistant to antibiotics and 
associated with a very high casefatality proportion. The substantial public health impact of 
HCA Acinetobacter infections underscores the importance of vigilant infection control 
practices and surveillance to detect breakdowns in prevention measures.
Our findings must be interpreted in light of certain limitations. One of our primary 
objectives was to define a group of patients with clear evidence of community-associated 
disease. Although our strict case definition reduced the possibility of an HCA infection 
being misclassified as non-HCA, it probably resulted in an underestimation of the true 
number of non-HCA infections. The presence of an HCA risk factor does not preclude the 
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possibility that the infection was acquired outside a healthcare facility. Another limitation 
was that only HCA risk factors recorded in the patient’s chart were captured. Additionally, 
we cannot rule out the possibility that some of these cases may have represented 
contamination rather than true infection. However, we tried to limit the inclusion of 
contaminated cultures by excluding those that grew additional organisms or became positive 
after 24 h of incubation.
Our study benefited from the availability from both enhanced microbiology capacity at 
hospital laboratories and confirmatory testing at the national reference laboratory. Although 
many isolates were identified as Acinetobacter at hospital laboratories, 12/70 isolates (17%) 
were only identified as Acinetobacter at the reference laboratory. Our findings high-light the 
value of strengthening laboratory capacity and the potential impact on clinical care.
Thorough assessment of HCA risk factors allowed us to identify likely community-
associated Acinetobacter infections with confidence and compare clinical and 
microbiological features of infections of individuals with and without known HCA 
exposures in a way that has not previously been done. More recent data from 2009 and 2010 
indicate that Acinetobacter species continue to be a cause of bacteraemia; 29 (2009) and 36 
(2010) patients had positive cultures <3 days after hospitalization that were not likely to be 
due to contamination. Our results indicate that Acinetobacter species may be an important 
cause of community-associated sepsis and pneumonia in rural Thailand and add to previous 
reports, which have not explored healthcare exposures. Prospective studies are needed to 
confirm and better describe the epidemiology and risk factors of community-associated 
infections.
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Defining healthcare- vs. non-healthcare-associated Acinetobacter bacteraemia cases in 
hospitalized patients with Acinetobacter-positive blood culture bacteraemia, Nakhon 
Phanom and Sa Kaeo provinces, Thailand, May 2005– December 2008. * Temperature ≥38 
°C, age-specific elevated white blood cell count (WBC) [32]: < 7 days old > 30 000; 7 days–
5 years >15 000; 6–17 years >13 500; ≥18 years >11 000 or WBC <5000. † 
Acb=Acinetobacter calcoaceticus–baumannii complex.
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Hospitalized patients with Acinetobacter bacteraemia by month for (a) Nakhon Phanom and 
(b) Sa Kaeo provinces, Thailand, May 2005–December 2008. * Surveillance started in 
November 2005. Non-healthcare-associated (HCA) indicates that the blood culture was 
collected <3 days after admission and the patient had no known HCA risk factors.
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Table 1
Characteristics of hospitalized patients with Acinetobacter bacteraemia with and without healthcare-associated 






 <1 year 3 (9·4) 3 (7·9)
 1–<5 years 6 (18·8) 6 (15·8)
 5–15 years 6 (18·8) 1 (2·6)
 16–64 years 12 (37·5) 12 (31·6)
 ≥65 years 5 (15·6) 16 (42·1) 0·04
Male, n (%) 20 (62·5) 20 (52·6) 0·47
Species
 Acb complex 18 (56·3) 30 (79·0)
 Non-Acb complex§ 14 (43·8) 8 (21·0) 0·04
Acb, Acinetobacter calcoaceticus–baumannii.
*
Non-HCA indicates that the blood culture was collected <3 days after admission and the patient had no known HCA risk factors.
†
There were 40 patients with HCA infections; two new-borns were excluded from analyses.
‡
Pearson’s χ2 test.
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Table 3
Clinical characteristics and potential risk factors of hospitalized patients with Acinetobacter bacteraemia with 







n (%)‡ P value§
Signs/symptoms at admission:
 Temperature ≥38 °C 28 (87·5) 28 (73·7) 0·15
 Fever history 26 (81·3) 25 (65·8) 0·15
 Elevated WBC∥ 11 (44·0) 22 (61·1) 0·19
 Cough 12 (41·4) 16 (42·1) 0·95
 Dyspnea 9 (29·0) 10 (28·6) 0·97
 Rales or crepitations 6 (18·8) 4 (10·8) 0·50
 Sputum production 2 (6·9) 6 (17·7) 0·27
 Any indication of respiratory illness 16 (51·6) 20 (57·1) 0·65
 Low haemoglobin¶ 14 (77·8) 23 (69·7) 0·74
Admission diagnoses
 Pneumonia 9 (28·1) 11 (28·9) 0·94
 Other respiratory illness 3 (9·4) 6 (15·8) 0·49
 Septicaemia 4 (12·5) 3 (7·9) 0·69
 Fever, unspecified 3 (9·4) 2 (5·3) 0·65
 Other infectious condition 5 (15·6) 5 (13·2) 0·77
 Other 7 (22·6) 8 (22·9) >0·99
Underlying illness
 Diabetes 4 (16·0) 11 (33·3) 0·14
 Chronic obstructive pulmonary disease 2 (8·7) 4 (12·5) 0·70
 Renal failure 0 (0·0) 5 (13·2) 0·06
 Heart disease 1 (4·4) 4 (12·5) 0·39
 HIV 1 (3·1) 2 (5·3) >0·99
 None identified 23 (71·9) 8 (21·1) <0·01
Other potential risk factors:
 Immunosuppressive therapy 0 (0·0) 4 (12·5) 0·13
 Intubation 0 (0·0) 3 (23·1) 0·04
 Smoking# 5 (33·3) 8 (30·8) >0·99
 Alcohol use# 5 (33·3) 5 (19·2) 0·45
Death 3 (9·4) 17 (44·7) <0·01
*
Non-HCA indicates that the blood culture was collected < 3 days after admission and the patient had no known HCA risk factors.
†
There were 40 patients with HCA infections, two newborns were excluded from analyses.
‡
Denominators exclude individuals with missing data.
§
P value from Pearson’s χ2test.
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∥
White blood cell count: <5 years, >1000/mm3; 6–17 years, >13500/mm; >17 years, >11000/mm3 [34].
¶
Under 5 years, <11 g/dl; 5–11 years, <11·5 g/dl; 12–14 years, <12 gm/dl; males ≥15 years, <13 g/dl; females ≥ 15 years, <12 g/dl (based on WHO 
classification of anaemia).
#
Among individuals aged ≥18 years.
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Table 4
Antimicrobial resistance in Acinetobacter calcoaceticus–baumannii complex isolated from blood cultures of 
hospitalized patients with and without healthcare-associated (HCA) risk factors, Nakhon Phanom and Sa Kaeo 










n (%)† P value‡




9 (52·9) 21§ (80·8) 0·05
Cefotaxime 12 (70·6) 22 (84·6) 0·44
Co-trimoxazole 5 (29·4) 18 (69·2) 0·01
Amikacin 10 (58·8) 11 (42·3) 0·29
Gentamicin 5 (29·4) 14 (53·9) 0·11
Imipenem 4 (23·5) 14 (53·9) 0·05
MDR∥ 4 (23·5) 8 (30·8) 0·73
*
Non-HCA indicates that the blood culture was collected <3 days after admission and the patient had no known HCA risk factors.
†
Denominators exclude individuals with missing data.
‡
P value from Pearson’s χ2 test.
∥
Multi-drug resistant (resistant to cefotaxime, amikacin, and imipenem).
§
One isolate was intermediately susceptible.
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